The Efficacy of Conventional Screening Versus mHealth Screening in Early Detection of Oral Potentially Malignant Disorders and Oral Cancer Amongst the Rural Population of Varanasi: A Prospective and Blinded Study
Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Jul 30, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring the effectiveness of using mobile health technology (often called mHealth) to detect early signs of oral cancer and pre-cancerous conditions in people living in rural areas of Varanasi, India. The goal is to improve awareness about oral cancer and help frontline health workers understand how to diagnose it better. The program will also include long-term monitoring to catch oral cancer at an earlier stage, which can lead to better treatment outcomes.
To participate in this study, individuals must be over 18 years old and have habits like smoking, chewing tobacco, or consuming alcohol. They may also be eligible if they have specific signs in their mouth, such as sores or unusual patches. However, those who have already been diagnosed with oral cancer or are currently being treated for other serious illnesses cannot join the study. Participants will have the opportunity to learn more about their oral health and contribute to important research that could help their community.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Positive for any one or more of the following:
- • All individuals aged above 18 years positive for habits (smoking and smokeless tobacco, chewing betel leaf, areca nut, paan masala, and/or regular use of alcohol)
- • Clinical signs/symptoms (non-healing ulcers, white/ red/red \& white patches in the mouth, restriction of mouth opening and swelling of the neck)
- • All individuals aged above 40 irrespective of habit/oral lesions
- Exclusion Criteria:
- • Individuals already diagnosed with oral cancer and undergoing treatment for oral cancer
- • Under treatment for tuberculosis or suffering from any acute illness/ debilitating systemic disorders
About Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSKCC) is a world-renowned institution dedicated to cancer treatment, research, and education. As a leading clinical trial sponsor, MSKCC focuses on advancing innovative cancer therapies through rigorous scientific investigation and collaboration. The center's multidisciplinary team of experts employs cutting-edge methodologies to design and conduct trials that aim to improve patient outcomes and enhance understanding of cancer biology. With a commitment to translating research findings into clinical practice, MSKCC plays a pivotal role in shaping the future of oncology care and ensuring that patients have access to the latest therapeutic advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Milind Rajadhyaksha, PhD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported